The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
Identifieur interne : 004C27 ( Main/Exploration ); précédent : 004C26; suivant : 004C28The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
Auteurs : J. Eric Ahlskog [États-Unis] ; Ryan J. Uitti [États-Unis] ; Michael K. O'Connor [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Joseph Y. Matsumoto [États-Unis] ; Kathy F. Stark [États-Unis] ; Margaret F. Turk [États-Unis] ; Omer L. Burnett [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Agonist, Antiparkinson agent, Brain (drug effects), Brain (radionuclide imaging), Brain (vertebrata), Brain Mapping, Carbidopa (administration & dosage), Carbidopa (adverse effects), Carrier Proteins (drug effects), Carrier Proteins (metabolism), Chemotherapy, Cocaine (analogs & derivatives), Cocaine (diagnostic use), Corpus Striatum (drug effects), Corpus Striatum (radionuclide imaging), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Plasma Membrane Transport Proteins, Dopamine agonist, Dopamine receptor, Dopamine transporter, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Drug Therapy, Combination, Emission tomography, Ergot derivatives, Exploration, Female, Human, Humans, Iodine Radioisotopes, Levodopa (administration & dosage), Levodopa (adverse effects), Male, Membrane Glycoproteins, Membrane Transport Proteins, Middle Aged, Motor Skills (drug effects), Nerve Tissue Proteins, Parkinson Disease (drug therapy), Parkinson Disease (radionuclide imaging), Parkinson disease, Parkinson's disease, Pergolide, Pergolide (administration & dosage), Pergolide (adverse effects), Photon, Putamen (drug effects), Putamen (radionuclide imaging), SPECT, Tomography, Emission-Computed, Single-Photon, [123I] β‐CIT.
- MESH :
- chemical , administration & dosage : Carbidopa, Dopamine Agonists, Levodopa, Pergolide.
- chemical , adverse effects : Carbidopa, Dopamine Agonists, Levodopa, Pergolide.
- chemical , analogs & derivatives : Cocaine.
- chemical , diagnostic use : Cocaine.
- drug effects : Brain, Carrier Proteins, Corpus Striatum, Motor Skills, Putamen.
- drug therapy : Parkinson Disease.
- chemical , metabolism : Carrier Proteins.
- radionuclide imaging : Brain, Corpus Striatum, Parkinson Disease, Putamen.
- Aged, Brain Mapping, Dopamine Plasma Membrane Transport Proteins, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Drug Therapy, Combination, Female, Humans, Iodine Radioisotopes, Male, Membrane Glycoproteins, Membrane Transport Proteins, Middle Aged, Nerve Tissue Proteins, Tomography, Emission-Computed, Single-Photon.
Abstract
Single‐photon emission computed tomography (SPECT) imaging with the dopamine transporter ligand, [123I] β‐CIT (2β‐carboxymethoxy‐3β‐[4‐iodophenyl] tropane), has been proposed as a means of measuring Parkinson's disease (PD) progression. To be useful in this role, however, [123I] β‐CIT imaging should not be influenced by the medications used to treat PD, including the dopamine agonist drugs such as pergolide. We assessed the effect of adjunctive pergolide administration on [123I] β‐CIT uptake in 12 patients with PD, who were being treated with levodopa, initiating pergolide therapy for motor fluctuations. Patients underwent [123I] β‐CIT imaging at baseline, subsequently while on pergolide therapy (6 weeks), and again 4 weeks after pergolide wash‐out. Uptake in the striatum was averaged for the two sides and expressed as (striatum − occipital)/occipital, with similar calculations for putamen and caudate. Consistent with PD, the patients' mean striatal and putamen uptake ratios at baseline were significantly less (p <0.001) than the mean values from 26 normal control subjects of similar age. During pergolide treatment, the striatal and putamen [123I] β‐CIT uptake ratios were each statistically similar to baseline, although there was a slight trend toward an increased striatal value (8% higher on pergolide; p = 0.105). Caudate [123I] β‐CIT uptake was 11% higher on pergolide therapy (nominal p = 0.042, but not significant when adjusted for multiple comparisons: p = 0.126). After pergolide wash‐out, the striatal, putamen, and caudate uptake ratios did not differ from baseline. Therefore, we found that pergolide therapy did not significantly affect [123I] β‐CIT SPECT imaging but we cannot exclude a small influence.
Url:
DOI: 10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000812
- to stream Istex, to step Curation: 000812
- to stream Istex, to step Checkpoint: 003393
- to stream Main, to step Merge: 007925
- to stream PascalFrancis, to step Corpus: 002C98
- to stream PascalFrancis, to step Curation: 000023
- to stream PascalFrancis, to step Checkpoint: 002D07
- to stream Main, to step Merge: 007B56
- to stream PubMed, to step Corpus: 004098
- to stream PubMed, to step Curation: 004098
- to stream PubMed, to step Checkpoint: 004090
- to stream Ncbi, to step Merge: 000153
- to stream Ncbi, to step Curation: 000153
- to stream Ncbi, to step Checkpoint: 000153
- to stream Main, to step Merge: 007697
- to stream Main, to step Curation: 004C27
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease</title><author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name></author><author><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name></author><author><name sortKey="O Connor, Michael K" sort="O Connor, Michael K" uniqKey="O Connor M" first="Michael K." last="O'Connor">Michael K. O'Connor</name></author><author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name></author><author><name sortKey="Matsumoto, Joseph Y" sort="Matsumoto, Joseph Y" uniqKey="Matsumoto J" first="Joseph Y." last="Matsumoto">Joseph Y. Matsumoto</name></author><author><name sortKey="Stark, Kathy F" sort="Stark, Kathy F" uniqKey="Stark K" first="Kathy F." last="Stark">Kathy F. Stark</name></author><author><name sortKey="Turk, Margaret F" sort="Turk, Margaret F" uniqKey="Turk M" first="Margaret F." last="Turk">Margaret F. Turk</name></author><author><name sortKey="Burnett, Omer L" sort="Burnett, Omer L" uniqKey="Burnett O" first="Omer L." last="Burnett">Omer L. Burnett</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8EAD6592CF98902FE2CD4D0353934E761EB627D2</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y</idno><idno type="url">https://api.istex.fr/document/8EAD6592CF98902FE2CD4D0353934E761EB627D2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000812</idno><idno type="wicri:Area/Istex/Curation">000812</idno><idno type="wicri:Area/Istex/Checkpoint">003393</idno><idno type="wicri:doubleKey">0885-3185:1999:Ahlskog J:the:effect:of</idno><idno type="wicri:Area/Main/Merge">007925</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:00-0008155</idno><idno type="wicri:Area/PascalFrancis/Corpus">002C98</idno><idno type="wicri:Area/PascalFrancis/Curation">000023</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002D07</idno><idno type="wicri:doubleKey">0885-3185:1999:Ahlskog J:the:effect:of</idno><idno type="wicri:Area/Main/Merge">007B56</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10584667</idno><idno type="wicri:Area/PubMed/Corpus">004098</idno><idno type="wicri:Area/PubMed/Curation">004098</idno><idno type="wicri:Area/PubMed/Checkpoint">004090</idno><idno type="wicri:Area/Ncbi/Merge">000153</idno><idno type="wicri:Area/Ncbi/Curation">000153</idno><idno type="wicri:Area/Ncbi/Checkpoint">000153</idno><idno type="wicri:doubleKey">0885-3185:1999:Ahlskog J:the:effect:of</idno><idno type="wicri:Area/Main/Merge">007697</idno><idno type="wicri:Area/Main/Curation">004C27</idno><idno type="wicri:Area/Main/Exploration">004C27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease</title><author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea></affiliation></author><author><name sortKey="O Connor, Michael K" sort="O Connor, Michael K" uniqKey="O Connor M" first="Michael K." last="O'Connor">Michael K. O'Connor</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Matsumoto, Joseph Y" sort="Matsumoto, Joseph Y" uniqKey="Matsumoto J" first="Joseph Y." last="Matsumoto">Joseph Y. Matsumoto</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea></affiliation></author><author><name sortKey="Stark, Kathy F" sort="Stark, Kathy F" uniqKey="Stark K" first="Kathy F." last="Stark">Kathy F. Stark</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Turk, Margaret F" sort="Turk, Margaret F" uniqKey="Turk M" first="Margaret F." last="Turk">Margaret F. Turk</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea></affiliation></author><author><name sortKey="Burnett, Omer L" sort="Burnett, Omer L" uniqKey="Burnett O" first="Omer L." last="Burnett">Omer L. Burnett</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Nuclear Medicine, Mayo Clinic, Jacksonville, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-11">1999-11</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="940">940</biblScope><biblScope unit="page" to="946">946</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8EAD6592CF98902FE2CD4D0353934E761EB627D2</idno><idno type="DOI">10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y</idno><idno type="ArticleID">MDS1005</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Agonist</term><term>Antiparkinson agent</term><term>Brain (drug effects)</term><term>Brain (radionuclide imaging)</term><term>Brain (vertebrata)</term><term>Brain Mapping</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (adverse effects)</term><term>Carrier Proteins (drug effects)</term><term>Carrier Proteins (metabolism)</term><term>Chemotherapy</term><term>Cocaine (analogs & derivatives)</term><term>Cocaine (diagnostic use)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (radionuclide imaging)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Dopamine agonist</term><term>Dopamine receptor</term><term>Dopamine transporter</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Combinations</term><term>Drug Therapy, Combination</term><term>Emission tomography</term><term>Ergot derivatives</term><term>Exploration</term><term>Female</term><term>Human</term><term>Humans</term><term>Iodine Radioisotopes</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Nerve Tissue Proteins</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pergolide</term><term>Pergolide (administration & dosage)</term><term>Pergolide (adverse effects)</term><term>Photon</term><term>Putamen (drug effects)</term><term>Putamen (radionuclide imaging)</term><term>SPECT</term><term>Tomography, Emission-Computed, Single-Photon</term><term>[123I] β‐CIT</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Carbidopa</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Carrier Proteins</term><term>Corpus Striatum</term><term>Motor Skills</term><term>Putamen</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Carrier Proteins</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term><term>Corpus Striatum</term><term>Parkinson Disease</term><term>Putamen</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Brain Mapping</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Combinations</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Iodine Radioisotopes</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins</term><term>Middle Aged</term><term>Nerve Tissue Proteins</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Encéphale</term><term>Ergot dérivé</term><term>Exploration</term><term>Homme</term><term>Parkinson maladie</term><term>Pergolide</term><term>Photon</term><term>Récepteur dopaminergique</term><term>Tomoscintigraphie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Single‐photon emission computed tomography (SPECT) imaging with the dopamine transporter ligand, [123I] β‐CIT (2β‐carboxymethoxy‐3β‐[4‐iodophenyl] tropane), has been proposed as a means of measuring Parkinson's disease (PD) progression. To be useful in this role, however, [123I] β‐CIT imaging should not be influenced by the medications used to treat PD, including the dopamine agonist drugs such as pergolide. We assessed the effect of adjunctive pergolide administration on [123I] β‐CIT uptake in 12 patients with PD, who were being treated with levodopa, initiating pergolide therapy for motor fluctuations. Patients underwent [123I] β‐CIT imaging at baseline, subsequently while on pergolide therapy (6 weeks), and again 4 weeks after pergolide wash‐out. Uptake in the striatum was averaged for the two sides and expressed as (striatum − occipital)/occipital, with similar calculations for putamen and caudate. Consistent with PD, the patients' mean striatal and putamen uptake ratios at baseline were significantly less (p <0.001) than the mean values from 26 normal control subjects of similar age. During pergolide treatment, the striatal and putamen [123I] β‐CIT uptake ratios were each statistically similar to baseline, although there was a slight trend toward an increased striatal value (8% higher on pergolide; p = 0.105). Caudate [123I] β‐CIT uptake was 11% higher on pergolide therapy (nominal p = 0.042, but not significant when adjusted for multiple comparisons: p = 0.126). After pergolide wash‐out, the striatal, putamen, and caudate uptake ratios did not differ from baseline. Therefore, we found that pergolide therapy did not significantly affect [123I] β‐CIT SPECT imaging but we cannot exclude a small influence.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li><li>Minnesota</li></region></list><tree><country name="États-Unis"><region name="Minnesota"><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name></region><name sortKey="Burnett, Omer L" sort="Burnett, Omer L" uniqKey="Burnett O" first="Omer L." last="Burnett">Omer L. Burnett</name><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name><name sortKey="Matsumoto, Joseph Y" sort="Matsumoto, Joseph Y" uniqKey="Matsumoto J" first="Joseph Y." last="Matsumoto">Joseph Y. Matsumoto</name><name sortKey="O Connor, Michael K" sort="O Connor, Michael K" uniqKey="O Connor M" first="Michael K." last="O'Connor">Michael K. O'Connor</name><name sortKey="Stark, Kathy F" sort="Stark, Kathy F" uniqKey="Stark K" first="Kathy F." last="Stark">Kathy F. Stark</name><name sortKey="Turk, Margaret F" sort="Turk, Margaret F" uniqKey="Turk M" first="Margaret F." last="Turk">Margaret F. Turk</name><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8EAD6592CF98902FE2CD4D0353934E761EB627D2
|texte= The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |